{
    "code": "02024596",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024596",
    "time": "2020-02-25 13:24:43",
    "許可證字號": "衛署藥輸字第024596號",
    "註銷狀態": "已註銷",
    "註銷日期": "102\/03\/22",
    "註銷理由": "自請註銷",
    "有效日期": "106\/01\/17",
    "發證日期": "96\/01\/17",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202459606",
    "中文品名": "凡事通錠30毫克",
    "英文品名": "Mirtazon 30mg tablets",
    "適應症": "鬱症。",
    "劑型": "116膜衣錠",
    "包裝": "3-1000錠鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "06須由醫師處方使用",
    "藥品分類": "",
    "主製造廠": {
        "限制項目": "02輸　入 25監視中學名藥",
        "申請商名稱": "620110T011  台灣英特威動物藥品股份有限公司",
        "申請商地址": "台北市信義區信義路五段106號12樓",
        "主製造廠": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "2816901700",
            "成分名稱": "MIRTAZAPINE",
            "含量描述": "",
            "含量": "30.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "02024596004___20111020.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024596&Seq=008&Type=9"
        },
        {
            "title": "020245960006.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024596&Seq=006&Type=8"
        }
    ]
}